Trials / Active Not Recruiting
Active Not RecruitingNCT04526782
ENCOrafenib With Binimetinib in bRAF NSCLC
A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 119 (estimated)
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Encorafenib 75 MG | 450 mg (6 × 75 mg capsule) per day |
| DRUG | Binimetinib 15 MG | 45 mg (3 × 15 mg tablet) twice daily |
Timeline
- Start date
- 2021-01-19
- Primary completion
- 2025-07-16
- Completion
- 2026-03-01
- First posted
- 2020-08-26
- Last updated
- 2025-11-18
Locations
36 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04526782. Inclusion in this directory is not an endorsement.